Big Shot: Developments in Prefilled Syringes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Big Shot: Developments in Prefilled Syringes
Many companies are coming up with innovative materials and manufacturing methods to feed the growing demand for prefilled syringes.


Pharmaceutical Technology


"There are robotics for all the steps, it's just a matter of getting them more accepted into the industry," says Isberg. "Moving toward automated processes, such as handling nested tubs, provides consistency, and the technology is becoming cheaper and more standardized. You just have to get past the company's fear of automation so they can understand the advantages of it."

Because the entire process can take place inside a barrier system, engineers are redesigning automated equipment to be smaller and narrower so as to provide operators an easy reach across them if necessary. Barrier systems not only protect the product from contamination and product operators from potent compounds, they also may protect operators from the robotics units inside the system. Isolator and RABs systems may be equipped with "light curtains" that detect when operators place their hands in the gloves and shuts the machinery down. Barrier systems are also equipped with various online sensors for fill volume, headspace analysis, particulate detection, and visual inspection.

"Those are all integrated into the filling system," says Isberg. "A lot of this technology wasn't available 10 to 15 years ago."

Reference

1. B. Verjans, J. Thilly, and C. Vandecasserie, "A New Concept in Aseptic Filling: Closed-Vial Technology," Aseptic Processing, supplement to Pharm. Technol. (May 2005).

2. J. Zimmermann, "Advances in Aseptic Manufacturing," presented at PDA Emerging Manufacturing and Quality Control Technologies, San Diego, CA, Jan. 30, 2007.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here